Corrigendum through General Announcement regarding disclosure of Pre-Preferential shareholding of Proposed allottees, Ultimate Beneficial Owners (UBO''s), Revised issue size of Proposed ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has issued a corrigendum updating its preferential allotment disclosures following the EGM held on October 22, 2025. The issue size has been revised downward from ₹153.25 crore to ₹149.49 crore, comprising 6,44,360 equity shares to non-promoters plus 5,51,600 convertible warrants (3,51,600 to non-promoters and 2,00,000 to promoter group), all for cash. Promoter holding will dilute from 48.93% to 42.42% on a fully diluted basis. The allotment list includes notable investors such as Alchemy Capital Management (with Estate of Late Rakesh Jhunjhunwala as UBO), NAV Capital Emerging Star Fund, and Capri Global Holdings. Funds will be used for brand marketing (35%), working capital (35%), strategic reserves (15%), capex, R&D, and contingency to fund expansion into pet care, nutraceuticals, and pharma generics segments.
The slight reduction in issue size and detailed UBO disclosures improve transparency for shareholders. The dilution of promoter stake from 48.93% to 42.42% means existing shareholders will see their proportional ownership reduced, though the capital raise supports business expansion. Presence of reputed investor names may lend credibility to the fundraising.